Clinical trials
Metabolic Dysfunction-Associated Steatotic Liver Disease clinical trials
Below are recruiting metabolic dysfunction-associated steatotic liver disease clinical trials, each written for real people, not researchers. We’re tracking 69 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06994871Enrolling by invitation
Exercise and liver fat in fatty liver disease
This study tests if different types of exercise can reduce fat in the liver for people with metabolic fatty liver disease. It might help if you are looking for a non-drug way to improve your liver health.
Nanjing, JiangsuAges 18–45 - NCT07001865Enrolling by invitation
Effects of healthy obesity on liver and uric acid risks
This study looks at people who are metabolically healthy but overweight or obese, and how that affects their risk of developing fatty liver disease (MASLD) or high uric acid levels (hyperuricemia). It aims to see if 'healthy' obesity still carries hidden health risks.
NingboAges 18–100 - NCT06984510Recruiting
Early aging and diabetes risk with fatty liver
This study looks at how early biological aging might increase the chance of developing type 2 diabetes in people with a fatty liver (a condition called MASLD). It uses routine health check-up data to understand the link.
Ningbo, ZhejiangAges 20–90 - NCT06986447Enrolling by invitation
Non-invasive tests for serious liver disease
This study is testing whether advanced imaging and other non-invasive methods can properly identify people with significant liver scarring due to metabolic liver disease or alcohol-related liver disease. It may help find better ways to track liver health without repeated needle biopsies.
Chandler, ArizonaAges 18–80 - NCT06953830Enrolling by invitation
Measuring spleen stiffness in veterans with fatty liver disease
This study tests a new way to measure spleen stiffness in veterans with metabolic-dysfunction fatty liver disease. It may help doctors better understand and monitor this condition without invasive procedures.
Columbia, South CarolinaAges 18 years+ - NCT06944353Enrolling by invitation
Fatty liver risk screening in the emergency department
This study looks at fatty liver findings on emergency department scans. If you have fatty liver and were sent home from the ED, the study may help connect you to follow-up care and avoid future liver problems.
Chicago, IllinoisAges 18 years+ - NCT06868992Recruiting
Study of MASH and cell changes in weight-loss surgery
This study looks at a possible link between MASH (liver inflammation with fat buildup) and tiny cell structures that help liver cells work. Researchers want to understand this better in people having weight-loss surgery, where a small liver sample will be taken.
Lyon, FranceAges 18–99 - NCT06836609RecruitingPhase 1/Phase 2
Study of a new drug for fatty liver disease (MASLD/MASH)
This study tests a new drug called ALN-CIDEB for people with fatty liver disease (MASLD or MASH). The goal is to see if it can reduce liver fat and improve liver health. You may qualify if you have a higher BMI and evidence of liver fat on imaging tests.
Chandler, ArizonaAges 18–65 - NCT06845345Enrolling by invitationPhase 4
Can a special diet or pills help liver health?
This study compares two treatments for liver scarring in people with overweight or related health issues. One group follows a special diet with restricted eating times, while the other takes a combination of two medications (naltrexone and bupropion). It aims to see which approach better improves liver fibrosis.
RotterdamAges 18–75 - NCT06843148Recruiting
Does niacin help move fat from liver to fat tissue?
This study tests if niacin (a B vitamin) can help the body store fat safely in fat tissue instead of letting it build up in the liver. It may be an option for people with fatty liver linked to belly fat, without serious liver damage or other health issues.
Sherbrooke, QuebecAges 20–80 - NCT06768216Recruiting
Mediterranean vs. low-fat diet for fatty liver in overweight kids
This trial compares two diets—a Mediterranean-style diet and a low-fat diet—to see which better reduces liver fat in overweight children and teens with fatty liver disease (MASLD). It aims to find a safe, effective eating plan for young people.
New Delhi, National Capital Territory of DelhiAges 8–18 - NCT06706856Recruiting
Ultrasound test for fatty liver disease in kids
This study explores if a new ultrasound technique can detect fatty liver disease in children. It aims to find a simpler, safer way to check liver health without needing an MRI or biopsy.
La Jolla, CaliforniaAges 9–18 - NCT06703450Enrolling by invitation
Liver fibrosis study with MRI for MASLD patients
This study is testing whether an MRI can help doctors see liver scarring (fibrosis) in people with MASLD, a type of fatty liver disease. It is for patients who already need a liver biopsy as part of their care, to compare the MRI results with the biopsy.
New York, New YorkAges 18–89 - NCT06506513Recruiting
Can exercise help fatty liver disease?
This study tests whether a program of physical activity can reduce fat in the muscles and liver of people with MASLD, a type of fatty liver disease linked to metabolism. It looks at how exercise might help improve liver health.
BrusselsAges 18–70 - NCT06374875RecruitingPhase 4
Does metabolic surgery reduce liver scarring?
This study tests if weight loss surgery can improve liver fibrosis (scarring) in people with obesity and advanced liver disease. It may help those considering surgery to know if their liver health can get better.
Phoenix, ArizonaAges 18–75 - NCT06318169RecruitingPhase 3
Testing pegozafermin for MASH and liver fibrosis
This trial tests an experimental drug called pegozafermin to see if it can help people with MASH (a fatty liver disease) and liver scarring (fibrosis). It's for people who have moderate-to-advanced scarring but not cirrhosis, and who have not had other serious liver conditions or poorly controlled diabetes.
Birmingham, AlabamaAges 18–80 - NCT06138821Recruiting
Endoscopic sleeve gastroplasty for obesity and MASH
This study tests if a procedure called endoscopic sleeve gastroplasty helps people with obesity and a liver condition called MASH lose weight and improve their liver health. It might be an option if you have both obesity and MASH and haven't had weight-loss surgery before.
Boston, MassachusettsAges 18 years+ - NCT05648214RecruitingPhase 1/Phase 2
Testing a new liver medicine in people with fatty liver
This early-phase study tests whether ALN-PNP is safe and well tolerated, first in healthy adults and then in adults with MASLD (fatty liver disease). If you have MASLD, it may help researchers learn whether this medicine is a promising option for treating liver fat buildup.
Glendale, CaliforniaAges 18–75 - NCT04873258Recruiting
Test a non-invasive tool to screen for fat-related liver disease
This study looks at a new non-invasive screening method to predict metabolic dysfunction–associated steatotic liver disease (MASLD), a condition where fat builds up in the liver. The goal is to help identify people who may be at risk without needing invasive tests.
London, LondonAges 18–80 - NCT06449339RecruitingPhase 4
Beta-blocker study for early-stage liver scarring
This study tests a medicine called carvedilol (a non-selective beta-blocker) to see if it can prevent complications in people with advanced chronic liver disease who are at high risk but haven't had serious problems like bleeding yet.
Hong KongAges 18 years+ - NCT07403604RecruitingPhase 1
Lowering Insulin to Reduce Fat Buildup in the Liver
This study tests if lowering insulin levels can reduce fat buildup in the liver for people with a fatty liver condition called MASLD. It's looking for adults who are overweight and have early signs of insulin resistance but not diabetes.
New York, New YorkAges 18–65
Hear when a new Metabolic Dysfunction-Associated Steatotic Liver Disease trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for metabolic dysfunction-associated steatotic liver disease?
- Yes. Clin2 currently lists 69 recruiting metabolic dysfunction-associated steatotic liver disease studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a metabolic dysfunction-associated steatotic liver disease trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a metabolic dysfunction-associated steatotic liver disease trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
- Metabolic Dysfunction-associated Fatty Liver Disease
- Metabolic Associated Steatotic Liver Disease
- Metabolic Dysfunction-Associated Liver Disease
- Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)
- MASH - Metabolic Dysfunction-Associated Steatohepatitis
- Metabolic Associated Fatty Liver Disease
- Liver Dysfunction
- Alcohol-associated Liver Disease
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.